SCHEMBL20873256

SCHEMBL20873256

COc1cccc(N2CCN(CC3=C[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)O3)CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ MAPT P10636 4/20 0.45
▸ TSHR P16473 2/20 0.44
▸ KCNH2 Q12809 2/20 0.44
▸ DRD2 P14416 1/20 0.44
▸ GFER P55789 4/20 0.43
▸ USP2 O75604 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ DRD4 P21917 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ APEX1 P27695 1/20 0.42
▸ RECQL P46063 1/20 0.42
▸ BLM P54132 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20873282 0.89 MEN1 (0.43) KDM4EALDH1A1SMN1; SMN2MAPTDRD2
SCHEMBL20873249 0.88 DRD4 (0.39) ALDH1A1MAPTTSHRDRD2DRD4
SCHEMBL20873301 0.82 DRD2 (0.36) KDM4EALDH1A1SMN1; SMN2MAPTTSHR
SCHEMBL20873260 0.82 SMN1; SMN2 (0.42) KDM4EALDH1A1SMN1; SMN2MAPTDRD2
SCHEMBL21112900 0.82 MAPT (0.51) KDM4EALDH1A1SMN1; SMN2MAPTTSHR
SCHEMBL21112944 0.80 ALDH1A1 (0.42) KDM4EALDH1A1DRD2DRD4HTR7
SCHEMBL20873320 0.75 ALDH1A1 (0.48) KDM4EALDH1A1SMN1; SMN2MAPTTSHR
SCHEMBL21112915 0.74 ALDH1A1 (0.46) KDM4EALDH1A1SMN1; SMN2MAPTTSHR
SCHEMBL20873248 0.71 ALDH1A1 (0.47) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
Hydrochloric Acid SCHEMBL8745028 0.69 KDM4E (0.68) KDM4EALDH1A1SMN1; SMN2MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed
EP-3463480-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN Sanofi (FR) 2019-04-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein GPR119, SLC2A8, SLC2A4 KDM4E 4398/4885ALDH1A1 1514/4885SMN1; SMN2 4049/4885
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 KDM4E 4398/4885ALDH1A1 1514/4885SMN1; SMN2 4049/4885
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 KDM4E 4398/4885ALDH1A1 1514/4885SMN1; SMN2 4049/4885
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 KDM4E 4398/4885ALDH1A1 1514/4885SMN1; SMN2 4049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback